Conditions: Neoplasms
Keywords: ADC PF-06664178 solid tumors tumors neoplasm metastasis NSCLC non small cell lung cancer OVCA ovarian cancer Phase 1 breast cancer
Enrollment: 31
Healthy volunteers: no

Brief summary:
To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Detailed description:

Arms:
arm 1: Experimental

Interventions: intervention 1: PF-06664178 intervention 2: PF-06664178
Intervention descriptions: intervention 1: Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined. intervention 2: Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.

Protocol document: